Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Mucosa Absorption of IN-C004 in Healthy Volunteers
NCT04654065Phase 1Completed
- Sponsor
- HK inno.N Corporation
- Start
- Jan 2021
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tegoprazan in gastroesophageal reflux disease (GERD), sponsored by HK inno.N Corporation. Primary endpoints: Area Under the Curve from time zero to last quantifiable concentration at 2 hours, Maximum Plasma Concentration at 2 hours and 1 more. Started Jan 2021; status: completed.
02
Drugs
tegoprazan
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT04654065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04654065.